ATE315033T1 - Subtituierte isoxazole derivate als estrogen rezeptor modulatore - Google Patents

Subtituierte isoxazole derivate als estrogen rezeptor modulatore

Info

Publication number
ATE315033T1
ATE315033T1 AT99940916T AT99940916T ATE315033T1 AT E315033 T1 ATE315033 T1 AT E315033T1 AT 99940916 T AT99940916 T AT 99940916T AT 99940916 T AT99940916 T AT 99940916T AT E315033 T1 ATE315033 T1 AT E315033T1
Authority
AT
Austria
Prior art keywords
estrogen receptor
subtituted
receptor modulators
isoxazole derivatives
compositions
Prior art date
Application number
AT99940916T
Other languages
English (en)
Inventor
Verena D Huebner
Xiaodong Lin
Ian James
Liya Chen
Manoj Desai
Jennifer C Moore
Beata Krywult
Thayalan Navaratnam
Rajinder Singh
Rob Trainor
Liang Wang
Original Assignee
Chiron Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiron Corp filed Critical Chiron Corp
Application granted granted Critical
Publication of ATE315033T1 publication Critical patent/ATE315033T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT99940916T 1998-08-07 1999-08-06 Subtituierte isoxazole derivate als estrogen rezeptor modulatore ATE315033T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9577398P 1998-08-07 1998-08-07

Publications (1)

Publication Number Publication Date
ATE315033T1 true ATE315033T1 (de) 2006-02-15

Family

ID=22253531

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99940916T ATE315033T1 (de) 1998-08-07 1999-08-06 Subtituierte isoxazole derivate als estrogen rezeptor modulatore

Country Status (8)

Country Link
US (4) US6262098B1 (de)
EP (1) EP1102755B1 (de)
JP (1) JP2002522425A (de)
AT (1) ATE315033T1 (de)
AU (1) AU5467699A (de)
DE (1) DE69929345T2 (de)
ES (1) ES2255294T3 (de)
WO (1) WO2000008001A1 (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6632447B1 (en) 1998-05-07 2003-10-14 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
US6410043B1 (en) 1998-05-07 2002-06-25 The University Of Tennessee Research Corporation Method for chemoprevention of prostate cancer
EP1102755B1 (de) * 1998-08-07 2006-01-04 Chiron Corporation Subtituierte isoxazole derivate als estrogen rezeptor modulatore
DE10039199A1 (de) * 2000-08-10 2002-02-21 Schering Ag Kombinationspräparate aus einem ERß selektiven Estrogen und einem SERM oder Antiestrogen
JP2002069061A (ja) * 2000-08-30 2002-03-08 Canon Inc オキサゾール化合物及びそれを用いた有機発光素子
US7022725B2 (en) 2000-11-17 2006-04-04 Takeda Pharmaceutical Company Limited Isoxazole derivatives
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
DE60131967D1 (de) * 2001-08-13 2008-01-31 Phenex Pharmaceuticals Ag Nr1h4-kern-rezeptor-bindende verbindungen
US20040044226A1 (en) * 2001-10-15 2004-03-04 Dininno Frank P. Estrogen receptor modulators
US20060269611A1 (en) * 2001-11-29 2006-11-30 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20080249183A1 (en) * 2001-11-29 2008-10-09 Steiner Mitchell S Treatment of androgen-deprivation induced osteoporosis
US20070197664A1 (en) * 2001-11-29 2007-08-23 Steiner Mitchell S Prevention and treatment of androgen-deprivation induced osteoporosis
US20040214898A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S. Methods for treating hot flashes
EP1862165A3 (de) * 2001-11-29 2008-06-25 GTX, Inc. Verhinderung und Behandlung von durch Androgenverfall hervorgerufenen Hitzewallungen
US20050080143A1 (en) * 2001-11-29 2005-04-14 Steiner Mitchell S. Treatment of androgen-deprivation induced osteoporosis
US7524866B2 (en) * 2001-11-29 2009-04-28 Gtx, Inc. Prevention and treatment of androgen—deprivation induced osteoporosis
US20040096510A1 (en) * 2001-11-29 2004-05-20 Steiner Mitchell S. Prevention and treatment of androgen-deprivation induced osteoporosis
US20040213841A1 (en) * 2001-11-29 2004-10-28 Steiner Mitchell S Methods for treating hot flashes and gynecomastia
PL371181A1 (en) * 2002-01-22 2005-06-13 Akzo Nobel N.V. Tibolone in the treatment of complaints associated with the administration of drugs which prevent the synthesis of endogenous estrogen
JP2006515838A (ja) * 2002-11-22 2006-06-08 スミスクライン ビーチャム コーポレーション ファルネソイドｘ受容体アゴニスト
US7332525B2 (en) 2003-01-17 2008-02-19 Castle Erik P Method of treatment of prostate cancer and composition for treatment thereof
EA009919B1 (ru) 2003-02-11 2008-04-28 Вернэлис (Кембридж) Лимитед Соединения изоксазола
ATE418551T1 (de) 2003-03-07 2009-01-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
DE602004016123D1 (de) 2003-03-07 2008-10-09 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US20070161698A1 (en) * 2003-05-30 2007-07-12 Microbia, Inc. Modulators of CRTH2 Activity
US7205329B2 (en) * 2003-05-30 2007-04-17 Microbia, Inc. Modulators of CRTH2 activity
CA2530808A1 (en) * 2003-07-01 2005-01-13 Microbia, Inc. Cox-2 and faah inhibitors
US20070293542A1 (en) * 2003-10-16 2007-12-20 Cali Brian M Selective Cox-2 Inhibitors
US8157788B2 (en) * 2003-11-06 2012-04-17 Paolo L. Manfredi Multi-site drug delivery platform
US8236861B2 (en) 2004-02-13 2012-08-07 Hormos Medical Corporation Method for enhancing the bioavailablity of ospemifene
US20050234244A1 (en) * 2004-04-20 2005-10-20 Wilmin Bartolini Synthesis of COX-2 and FAAH inhibitors
US20050234030A1 (en) * 2004-04-20 2005-10-20 Wilmin Bartolini Modulators of CRTH2, COX-2 and FAAH
WO2005113519A1 (en) * 2004-05-14 2005-12-01 Irm Llc Compounds and compositions as ppar modulators
US20090082322A1 (en) * 2004-10-09 2009-03-26 The Regents Of The University Of Michigan Gender Differences in Experimental Aortic Aneurysm Formation
EP1799212A2 (de) 2004-10-13 2007-06-27 PTC Therapeutics, Inc. Verbindungen zur nonsense-unterdrückung und verfahren zu deren verwendung
WO2007037782A2 (en) * 2005-02-08 2007-04-05 The University Of North Carolina At Chapel Hill Method for treating prostate conditions
US8546451B2 (en) 2005-11-28 2013-10-01 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9409856B2 (en) 2005-11-28 2016-08-09 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
MX2008006885A (es) * 2005-11-28 2008-10-20 Gtx Inc Agentes de enlace de receptores nucleares.
NL2000351C2 (nl) * 2005-12-22 2007-09-11 Pfizer Prod Inc Estrogeen-modulatoren.
US8524663B2 (en) 2006-03-03 2013-09-03 New York University Method for site-specific polyvalent display on polymers
CA2659155A1 (en) * 2006-07-20 2008-01-24 Amgen Inc. Substituted azole aromatic heterocycles as inhibitors of 11.beta.-hsd-1
DE102007040243A1 (de) * 2007-08-25 2009-02-26 Universität des Saarlandes 17Beta-Hydroxysteriod-Dehydrogenase Typ1 Inhibitoren zur Behandlung hormonabhängiger Erkrankungen
NZ585389A (en) 2007-10-16 2011-10-28 Repros Therapeutics Inc Trans-clomiphene for metabolic syndrome
FI20070897A0 (fi) * 2007-11-23 2007-11-23 Juha Pulkkinen Uudet estrogeeniaktiivisuutta omaavat 4,5-dihydroisoksatsolit
US7618973B2 (en) * 2007-12-04 2009-11-17 Hoffmann-La Roche Inc. Isoxazolo-pyrazine derivatives
AU2008333326B2 (en) * 2007-12-04 2013-05-30 F. Hoffmann-La Roche Ag Isoxazolo-pyridine derivatives
US7943619B2 (en) * 2007-12-04 2011-05-17 Hoffmann-La Roche Inc. Isoxazolo-pyridazine derivatives
US9624161B2 (en) 2009-02-23 2017-04-18 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
US9427418B2 (en) 2009-02-23 2016-08-30 Gtx, Inc. Estrogen receptor ligands and methods of use thereof
WO2011009484A1 (en) * 2009-07-22 2011-01-27 Novartis Ag Arylpyrazoles and arylisoxazoles and their use as pkd modulators
US9216972B2 (en) 2009-10-29 2015-12-22 Bristol-Myers Squibb Company Tricyclic heterocyclic compounds
WO2012052395A1 (en) 2010-10-18 2012-04-26 N. V. Organon Isoxazole derivatives used as oestrogen modulators
US8604062B2 (en) 2011-10-20 2013-12-10 Hoffman-La Roche Inc. Process for the preparation of isoxazolyl-methoxy nicotinic acids
US8785435B2 (en) 2011-10-20 2014-07-22 Hoffmann-La Roche Inc. Solid forms
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
CA2856520C (en) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
RU2666530C2 (ru) * 2012-01-12 2018-09-11 Йейл Юниверсити Соединения и способы усиления деградации белков-мишеней и других полипептидов с помощью е3 убиквитин лигазы
CA2865234A1 (en) 2012-02-29 2013-09-06 Repros Therapeutics Inc. Combination therapy for treating androgen deficiency
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
BR112016010094B1 (pt) * 2013-11-05 2020-09-29 Bayer Cropscience Aktiengesellschaft Benzamidas substituídas para tratamento de artrópodes
US20170266166A1 (en) * 2014-05-17 2017-09-21 University Of Rochester Compositions and Methods to Inhibit Estrogen Receptor Beta for the Treatment of Renal Cell Carcinoma
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
CN108348605B (zh) 2015-11-10 2023-06-09 帕拉卡林治疗公司 用pdgf-cc抑制剂和抗雌激素治疗er阴性乳癌
US10398689B2 (en) * 2015-12-22 2019-09-03 Jiangsu Hengrui Medicine Co., Ltd. Benzopiperidine derivative, preparation method thereof and medical use thereof
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
CA3020153A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
GB201706806D0 (en) 2017-04-28 2017-06-14 Sentinel Oncology Ltd Pharmaceutical compounds
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
CN115710234B (zh) * 2022-11-02 2024-04-16 华南理工大学 一类具有抗肿瘤活性的3,4,5-三取代异噁唑类化合物及其制备方法和应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE295360C (de)
DE295630C (de)
FR2104932A1 (en) 1970-09-08 1972-04-28 Ferlux O-hydroxyphenyl pyrazoles - hypocholesterolemics anti inflammatories analgesics etc
DE2250343A1 (de) 1972-10-13 1974-04-18 Thiemann Chem Pharm Fab 4,6-disubstituierte resorcinverbindungen
ZA744908B (en) 1973-09-17 1975-08-27 American Cyanamid Co Catalytic dehydrogenation process for the preparation of 3,5-disubstituted pyrazoles
US4112108A (en) * 1976-12-06 1978-09-05 Sandoz, Inc. Isoxazolyl benzamides
US4229204A (en) * 1978-12-04 1980-10-21 Monsanto Company Trifluoromethylphenyl isoxazolyl benzoates
JPS5583766A (en) 1978-12-18 1980-06-24 Sankyo Co Ltd Isoxazolin-3-one derivative
US4268678A (en) 1979-09-04 1981-05-19 Sterling Drug Inc. 4-(Arylaliphatic)isoxazoles
CA1128526A (en) * 1979-10-05 1982-07-27 Cdc Life Sciences Inc. 3,4-diarylisoxazol-5-acetic acids
DE3119727A1 (de) * 1981-05-18 1982-12-02 Sterling Drug Inc., 10019 New York, N.Y. "4-(arylaliphatische)-isoxazole, welche als antivirale mittel nuetzlich sind, und deren herstellung"
DD295630A5 (de) 1987-07-03 1991-11-07 Akad Wissenschaften Verfahren zur herstellung von beta-lactamantibiotika
DD295360A5 (de) 1987-07-03 1991-10-31 Akad Wissenschaften Verfahren zur Herstellung von aktivierten Carbonsäureestern
DE3832570A1 (de) 1988-09-24 1990-03-29 Hoechst Ag 7-substituierte derivate der 3,5-dihydroxyhept-6-insaeure, verfahren zur ihrer herstellung, ihre verwendung als arzneimittel, sowie zwischenprodukte
US5116839A (en) 1989-06-26 1992-05-26 Sankyo Company, Limited Use of isoxazolin-3-one derivatives as antidepressants
JP2786683B2 (ja) 1989-08-15 1998-08-13 三共株式会社 グリコール誘導体およびその用途
JO1645B1 (en) 1989-12-26 1991-11-27 شركة جانسين فارماسوتيكا ان. في Pyridazine compounds are antibacterial viruses
JPH03208044A (ja) 1990-01-10 1991-09-11 Fuji Photo Film Co Ltd ハロゲン化銀写真感光材料
CA2036192A1 (en) 1990-02-13 1991-08-14 Nicholas Meanwell Heterocyclic carboxylic acids and esters
ATE108448T1 (de) 1990-05-11 1994-07-15 Sankyo Co Piperdinyloxy- und chinindidinyloxy- isoxazol- derivate, ihre herstellung und ihre therapeutische verwendung.
DE4126543A1 (de) 1991-08-10 1993-02-11 Chem & Pharm Patent Hold Ltd 3(5)-(hydroxyaryl)-pyrazole und ihre verwendung als wirkstoffe in arzneimittel
DE4129779A1 (de) * 1991-09-07 1993-03-11 Boehringer Mannheim Gmbh Neue tricyclische thiazol- und oxazol-derivate und diese enthaltende arzneimittel
DE4230839A1 (de) 1991-09-18 1993-03-25 Ciba Geigy Ag Polyarylenether mit pyrazoleinheiten
CA2099630A1 (en) 1992-07-02 1994-01-03 Guy Dominic Diana Heterocyclyl-phenoxyalkyl-piperidinylpyridazines as antiviral agents
JPH06135948A (ja) * 1992-10-30 1994-05-17 Taiho Yakuhin Kogyo Kk スチレン誘導体又はその塩
TW240217B (de) 1992-12-30 1995-02-11 Glaxo Group Ltd
AU5891494A (en) 1993-01-29 1994-08-15 Nippon Soda Co., Ltd. Heterocyclic derivative
AU6010594A (en) 1993-02-12 1994-08-29 Sankyo Company Limited Isoxazoleoxy derivative
IT1266582B1 (it) 1993-07-30 1997-01-09 Recordati Chem Pharm Derivati (di)azacicloesanici e diazacicloeptanici
WO1995006032A1 (en) 1993-08-20 1995-03-02 Banyu Pharmaceutical Co., Ltd. Tyrosine kinase inhibitor
IL111613A0 (en) 1993-11-12 1995-01-24 Rhone Poulenc Rorer Ltd Substituted phenyl compounds, their preparation and pharmaceutical compositions containing them
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
JPH07215952A (ja) 1993-12-06 1995-08-15 Otsuka Pharmaceut Factory Inc カテコール誘導体
US5547967A (en) 1993-12-08 1996-08-20 Kali-Chemie Pharma Gmbh (Phenylalkylaminoalkyloxy)-heteroaryl-compounds, processes and intermediates for their production and pharmaceutical compositions containing them
NZ278667A (en) * 1994-03-09 2000-12-22 Pfizer Use of isoxazoline derivatives to inhibit TNF production
DE4408084A1 (de) * 1994-03-10 1995-09-14 Hoechst Ag 3,5-Disubstituierte und 3,4,5-trisubstituierte 2-Isoxazoline und Isoxazole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US5547975A (en) * 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
CA2212836C (en) * 1995-02-13 2003-08-12 G.D. Searle & Co. Substituted isoxazoles for the treatment of inflammation
JP3208044B2 (ja) 1995-06-07 2001-09-10 東京エレクトロン株式会社 プラズマ処理装置及びプラズマ処理方法
JPH11508267A (ja) 1995-06-26 1999-07-21 藤沢薬品工業株式会社 ピラゾール化合物および医薬組成物
US5861359A (en) 1995-07-25 1999-01-19 Fmc Corporation Herbicidal phenylmethoxphenyl heterocycles
US6030970A (en) * 1995-08-02 2000-02-29 Smithkline Beecham Corporation Endothelin receptor antagonists
EP0761654B1 (de) 1995-08-24 2003-06-18 Basf Aktiengesellschaft Isoxazole- und Isothiazole-5-carboxamid Derivate, deren Herstellung und deren Verwendung als Herbizide
US6020121A (en) 1995-09-29 2000-02-01 Microcide Pharmaceuticals, Inc. Inhibitors of regulatory pathways
JPH09291082A (ja) * 1996-02-27 1997-11-11 Sankyo Co Ltd イソキサゾール誘導体
AU2151897A (en) * 1996-03-15 1997-10-10 Aarhus Universitets Forskningsfond Bis-heterocyclic derivatives
AUPO044596A0 (en) * 1996-06-14 1996-07-11 Skop Gmbh Ltd Improved electrical signal supply
DK0920422T3 (da) * 1996-08-14 2003-03-17 Searle & Co Krystallinsk form af 4-[5-methyl-3-phenylisoxazol-4-yl]benzensulfonamid
US6187797B1 (en) * 1996-12-23 2001-02-13 Dupont Pharmaceuticals Company Phenyl-isoxazoles as factor XA Inhibitors
AU727654B2 (en) * 1997-06-13 2000-12-21 Yamanouchi Pharmaceutical Co., Ltd. Tricyclic pyrazole derivative
WO1999041244A1 (en) * 1998-02-13 1999-08-19 Pharmacia & Upjohn Company Substituted aminophenyl isoxazoline derivatives useful as antimicrobials
EA200001035A1 (ru) * 1998-04-08 2001-04-23 Эли Лилли Энд Компани Способ ингибирования mrp1
EP1102755B1 (de) * 1998-08-07 2006-01-04 Chiron Corporation Subtituierte isoxazole derivate als estrogen rezeptor modulatore
ES2216579T3 (es) * 1998-10-09 2004-10-16 Janssen Pharmaceutica N.V. Derivados de 4,5-dihidro-isoxazol y su uso farmaceutico.
ATE296820T1 (de) 1999-06-03 2005-06-15 Teikoku Hormone Mfg Co Ltd Substituierte pyrazol-derivate
DE19953024A1 (de) * 1999-11-04 2001-05-10 Merck Patent Gmbh Isoxazolderivate als Phosphodiesterase VII-Hemmer
HUP0203536A3 (en) * 1999-12-02 2005-03-29 Basf Ag 3-(4,5-dihydroisoxazol-3-yl)-substituted benzoylpyrazoles as herbicides
US6579880B2 (en) * 2000-06-06 2003-06-17 Ortho-Mcneil Pharmaceutical, Inc. Isoxazoles and oxadiazoles as anti-inflammatory inhibitors of IL-8
US6495582B1 (en) * 2000-09-15 2002-12-17 Vertex Pharmaceuticals Incorporated Isoxazole compositions useful as inhibitors of ERK
US6624311B2 (en) * 2000-10-27 2003-09-23 Bristol-Myers Squibb Pharma Company Enantioselective enzymatic aminolysis of a racemic 2-isoxazolylacetate alkyl ester

Also Published As

Publication number Publication date
DE69929345D1 (de) 2006-03-30
JP2002522425A (ja) 2002-07-23
ES2255294T3 (es) 2006-06-16
US6387920B2 (en) 2002-05-14
US20010036956A1 (en) 2001-11-01
WO2000008001A1 (en) 2000-02-17
US6869969B2 (en) 2005-03-22
US6262098B1 (en) 2001-07-17
AU5467699A (en) 2000-02-28
US20030065012A1 (en) 2003-04-03
US20040102498A1 (en) 2004-05-27
DE69929345T2 (de) 2006-09-21
US6743815B2 (en) 2004-06-01
EP1102755A1 (de) 2001-05-30
EP1102755B1 (de) 2006-01-04

Similar Documents

Publication Publication Date Title
ATE315033T1 (de) Subtituierte isoxazole derivate als estrogen rezeptor modulatore
DE69935335D1 (de) Pyrazole als modulatoren des östrogenrezeptors
YU596A (sh) Estrogen agonisti/antagonisti
YU7797A (sh) Kombinovana terapija za osteoporozu
AU4926301A (en) Lpa receptor agonists and antagonists and methods of use
DE69914726D1 (de) Zusammensetzung zur regulierung des hauterscheinungsbildes
DE69930835D1 (de) Bicyclische pyridin-und pyrimidinderivate als neuropeptid y rezeptorantagonisten
TW427989B (en) Mesylate trihydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one
BR0006265A (pt) Composto de tetrahidroisoquinolinas como agonistas/antagonistas de estrogênios
NO20022655D0 (no) <Beta>-2-adrenerge reseptoragonister
BR0010215A (pt) Derivados de indolina como antagonistas de progesterona
ES2168650T3 (es) Compuestos y metodos moduladores de receptores de androgenos.
BR9510486A (pt) Compostos moduladores de receptores de esteróide e métodos
DE60205776D1 (en) Indolinon-derivative als protein-kinasehemmer
AP9801269A0 (en) Prostaglandin agonists.
BG104930A (en) 2-phenyl-1-[2-(-aminoethoxy)-benzyl]-indole in combination with estrogens
ZA971279B (en) Use of 5ht4 receptor antagonists for overcoming gastrointestinal effects of serotonin reuptake inhinitors
UA50808C2 (uk) Композиція для лікування респіраторного дистрес-синдрому дорослих або респіраторного дистрес-синдрому новонароджених
MXPA04005784A (es) 2-fenilbenzofuranos sustituidos como agentes estrogenitos.
FR2783707B1 (fr) Composition de maquillage comprenant une poly-alpha-olefine
UA72948C2 (uk) Заміщені похідні фенілпіперазину, фармацевтична композиція та спосіб лікування афективних або неврологічних захворювань і розладів
GB2340751B (en) Pharmaceutical compositions
TR200100885T2 (tr) 2-Metil-tieno-benzodiazepin formülasyonu
DK1079851T3 (da) Anvendelse af anti-prolactinmidler til behandling af cancer
AU2001245209A1 (en) Screening methods for bone morphogenetic mimetics

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1102755

Country of ref document: EP

REN Ceased due to non-payment of the annual fee